|
License Agreements (Details Textual)
|
12 Months Ended | 78 Months Ended | 0 Months Ended | 12 Months Ended | 3 Months Ended | 4 Months Ended | 12 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
USD ($)
|
Dec. 31, 2011
USD ($)
|
Dec. 31, 2012
USD ($)
|
Jan. 07, 2011
Asphelia Asset Purchase [Member]
USD ($)
|
Dec. 31, 2012
Asphelia Asset Purchase [Member]
USD ($)
|
Mar. 31, 2012
Falk [Member]
USD ($)
|
Mar. 31, 2012
Falk [Member]
EUR (€)
|
Apr. 30, 2012
Falk [Member]
USD ($)
|
Apr. 30, 2012
Falk [Member]
EUR (€)
|
Dec. 31, 2012
Falk [Member]
USD ($)
|
Dec. 31, 2012
Falk [Member]
EUR (€)
|
Nov. 30, 2007
UCLB [Member]
USD ($)
|
Mar. 31, 2012
UCLB [Member]
USD ($)
|
Dec. 31, 2012
UCLB [Member]
USD ($)
|
Dec. 31, 2012
UCLB [Member]
Maximum [Member]
|
Dec. 31, 2012
UCLB [Member]
Minimum [Member]
|
Dec. 31, 2010
Burnham [Member]
USD ($)
|
Jan. 07, 2011
Ovamed [Member]
USD ($)
|
Dec. 31, 2012
Ovamed [Member]
USD ($)
|
|
| License Agreements (Textual) [Abstract] | |||||||||||||||||||
| Date of acquisition | Jan. 07, 2011 | ||||||||||||||||||
| Payment for purchase of assets | $ 20,706,000 | ||||||||||||||||||
| Number of Series B Shares issued | 2,525,677 | ||||||||||||||||||
| Series B Convertible Preferred Stock issued, per share | $ 6.38 | ||||||||||||||||||
| PCP Note, principal amount | 750,000 | ||||||||||||||||||
| Cash paid for asset purchase | 3,809,000 | ||||||||||||||||||
| Payment to related party | 61,000 | 3,400,000 | |||||||||||||||||
| Repayment of Asphelia's debt | 400,000 | ||||||||||||||||||
| Acquired in-process research and development | 1,043,000 | 20,706,000 | 21,749,000 | 20,700,000 | |||||||||||||||
| Contingent milestone payments to OvaMed | 5,450,000 | ||||||||||||||||||
| Milestone payments to related party | 1,400,000 | 1,000,000 | 1,500,000 | ||||||||||||||||
| Current expiry date of Supply Agreement | 2013-03 | ||||||||||||||||||
| Automatic renewal of OvaMed Supply Agreement | 1 year | ||||||||||||||||||
| Prior notice period for non renewal of OvaMed Supply Agreement | 12 months | ||||||||||||||||||
| Cash paid to Falk | 6,500,000 | 5,000,000 | |||||||||||||||||
| Royalty payable to Falk | 1.00% | 1.00% | |||||||||||||||||
| Additional payments to Falk | 2,000,000 | 1,500,000 | |||||||||||||||||
| Remaining amount payable to Falk | 3,400,000 | 2,500,000 | |||||||||||||||||
| Percentage responsibility for clinical testing | 50.00% | 50.00% | |||||||||||||||||
| Total amount paid for purchase of manufacturing agreement | 1,500,000 | ||||||||||||||||||
| Related Party Transaction Equal Installment Amount | 500,000 | ||||||||||||||||||
| Property lease period | 5 years | ||||||||||||||||||
| Net present value | 1,000,000 | ||||||||||||||||||
| Upfront payment for license | 100,000 | ||||||||||||||||||
| Future milestone payment | 22,000,000 | ||||||||||||||||||
| Recognition of milestone payment | 250,000 | ||||||||||||||||||
| Royalty percentage | 5.00% | 3.00% | |||||||||||||||||
| Agreement termination notice period | 30 days | ||||||||||||||||||
| Upfront fee for amendment of license | 50,000 | ||||||||||||||||||
| Additional upfront fee for amendment of license | $ 25,000 | ||||||||||||||||||
| Management fee right to reduce transfer fee component agreed days | 10 days | ||||||||||||||||||
| Management fee right to reduce transfer fee component additional amount agreed days | 90 days | ||||||||||||||||||